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Aims To examine whether self-rated disease-specific and generic quality of life predicts long-term mortality, independent of




A cohort of 661 patients (62% male; age 71 years; left ventricular ejection fraction 34%) was followed prospectively
for 3 years. Quality of life questionnaires (Ladder of Life, RAND36, and Minnesota Living with Heart Failure Ques-
tionnaire) and BNP levels were assessed at discharge after a hospital admission for HF. Three-year mortality was 42%.
After adjustment for demographic variables, clinical variables, and BNP levels, poor quality of life scores predicted
higher mortality; per 10 units on the physical functioning [hazard ratio (HR) 1.08, 95% confidence interval (CI)
1.02–1.14] and general health (HR 1.08, 95% CI 1.01–1.16) dimensions of the RAND36. Patients with low scores
on these dimensions were more likely to be in New York Heart Association class III– IV, diagnosed with co-morbid-
ities, have suffered longer from HF, have lower estimated glomerular filtration rates, and have fewer beta-blocker
prescriptions.
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Introduction
Heart failure (HF) has a negative impact on the length and quality
of life (QoL) of patients.1,2 Studies on whether QoL in itself has
prognostic power for the prediction of mortality are inconsistent.
Some, but not all, studies have found an association between
poorer QoL and worse survival.3 Inconsistencies in previous
studies may be explained by their using different QoL instruments
to predict outcomes. Most studies used one questionnaire, or
focused on one subscale or question from a specific QoL question-
naire. Only a few have used disease-generic QoL questionnaires
[Short Form-36 Health Survey (SF-36)] simultaneously with
disease-specific QoL questionnaires [Minnesota Living with Heart
Failure questionnaire (MLwHFQ), Kansas City Cardiomyopathy
Questionnaire] in their patient population to describe the associ-
ation between QoL and survival in HF patients.3 Inconsistencies
may also arise from the different follow-up periods used in the dif-
ferent studies, which ranged from a couple of months to. 5 years,
and each study adjusted for different demographic and clinical vari-
ables.4 –8 The majority of studies did adjust for disease severity by
using left ventricular ejection fraction (LVEF) or the New York
Heart Association (NYHA) functional class.3 However, both
NYHA and LVEF have limitations as markers for disease severity.
LVEF only reflects the severity of LV systolic dysfunction and not
the severity of HF,9 whereas NYHA classification is highly subject-
ive based on the endurance of the patient and is directly associated
with (physical) QoL. Furthermore, the utility of NYHA classifica-
tion used as a marker of disease severity is currently the subject
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of some debate owing to low inter-rater reliability.10 Brain natri-
uretic peptide (BNP) has in recent years emerged as a reliable re-
flection of the severity of HF.11 None of the aforementioned
studies used BNP as a marker for the severity of HF.
Provided that QoL is a predictor of mortality, the important
next step is to find out which patients have a low QoL. In order
to reduce mortality, these patients in particular could benefit
most from additional treatment, focused on improving QoL.
To gain more insight into the prognostic value of QoL, we
examined the predictive value of several QoL instruments for long-
term mortality in a large group of HF patients. In order to control
with an objective parameter for the severity of HF, we adjusted for
plasma levels of BNP in our analyses. Additionally, we examined
the characteristics of patients with high and low QoL scores.
Methods
Patient population
Data were collected as part of the COACH study (Coordinating study
evaluating Outcomes of Advising and Counselling in Heart failure).
COACH was a multicentre, randomized clinical trial on the effect of
a disease management programme in HF; the design, main results,
and first QoL data have been published.2,12 –14 In brief, 1023 patients
from 17 hospitals in The Netherlands were enrolled in the COACH
study. Patients were included in the study during a hospitalization for
HF (NYHA functional class II– IV), with HF as the primary diagnosis.
The diagnosis was based on a combination of typical signs and symp-
toms according to the European Society of Cardiology (ESC) guide-
lines15 for which a hospital stay was considered necessary. During
hospitalization, all patients received standard care, both pharmaco-
logical and non-pharmacological, according to the guidelines,15 in a car-
diology ward, staffed by cardiologists and registered nurses. Patients
were 18 years or older and had evidence of structural underlying
heart disease. Exclusion criteria were: concurrent inclusion in a study
requiring additional visits to research healthcare personnel; restrictions
that made the patient unable to fill in data collection forms; an invasive
intervention within the last 6 months or planned during the following 3
months; or ongoing evaluation for heart transplantation. All patients
gave written informed consent.
The Central Ethics Committee approved the study protocol and the
extended 3-year follow-up data collection on survival. The study was
performed in accordance with the principles outlined in the Declar-
ation of Helsinki.
Data collection
Plasma BNP levels were determined once and analysed locally within
4 h of blood collection (1 mL of blood, collected in EDTA), on the
day of hospital discharge or on the day before hospital discharge. All
BNP measurements were performed using a fluorescence immuno-
assay kit (Triagew; Biosite Incorporated, San Diego, CA, USA).16
Data on LV function were obtained by standard transthoracic
echocardiography.
Survival data were collected during the 18-month follow-up period
of the COACH study as part of the primary endpoint of the study.
Cause of death and the date of the event were adjudicated by a
central endpoints committee. Concerning the patients who survived
the 18-month follow-up period, 3-year follow-up (1095 days) data
on all-cause mortality were collected from the hospital registry, and
the general practitioner and/or municipality, 3 years after the last
patients was included in the COACH study. For each patient who sur-
vived the initial 18-month follow-up, but died afterwards, a calculation
was made on the time period between dying and inclusion in the
COACH study in order to have an equally long follow-up period for
each patient (1095 days).
Data on QoL were collected during hospitalization. Quality of life
was assessed in three different ways: global well-being, disease-generic
QoL, and disease-specific QoL.
Global well-being was assessed by Cantril’s Ladder of Life. This is a
single-item measure which asks the patient to rate their sense of well-
being on a ladder, with 10 reflecting the best possible life imaginable
and 0 reflecting the worst possible life imaginable. Cantril’s Ladder
of Life has been used in various cardiovascular studies and is consid-
ered to be a valid measure of global well-being.17 A higher score indi-
cates better well-being.18
Disease-generic QoL was assessed by the Medical Outcome Study
36-item General Health Survey (RAND36), a self-report questionnaire
of general health status and comparable with the SF-36.19,20 The
RAND36 is a well-validated generic, 36-item questionnaire that
includes nine health concepts that represent dimensions of QoL: phys-
ical functioning, social functioning, role limitations because of physical
functioning, role limitations because of emotional functioning, mental
health, vitality, bodily pain, general health, and perceived health
change. Each dimension has a score between 0 and 100; a higher
score means better health.19
Disease-specific QoL was measured with the MLwHFQ.21 The
MLwHFQ is a 21-item scale, with a scoring range of zero for no impair-
ment, to 105 for maximum impairment as a result of HF. Three scores
can be determined: a total score (21 items, 0–105), the physical di-
mension (8 items, 0–40), and the emotional dimension (5 items, 0–
25). Higher scores mean a worse QoL. The questions cover symptoms
and signs relevant to HF, e.g. physical activity, social interaction, sexual
activity, work, and emotions. All patients were instructed by trained
data collectors to report if, and to what extent, HF has affected
their life during the last month on each item. The reliability and validity
of the MLwHFQ have been documented.21
Statistical analysis
Descriptive statistics were used to characterize the study population.
Data are presented as means+ standard deviations (SDs) or percen-
tagess. Student’s t-tests and Mann–Whitney tests for continuous
variables, and x2 tests for categorical variables were performed to
compare demographic characteristics, clinical characteristics, and
QoL between patients who survived and did not survive the 3-year
follow-up period. Cox proportional hazards regression was used to
determine the independent association of QoL with time to mortality.
Separate analyses were made for each scale: the nine dimensions of the
RAND36, both subscales and total score of the MLwHFQ, and the
Ladder of Life. To evaluate a possible effect-modifying role of potential
risk factors with regard to mortality, three Cox regression analyses
were performed: first including the QoL scale, secondly adjusting for
age and gender, and finally adjusting for all variables with a theoretical
or univariate association with mortality (P-value ,0.10 two tailed).
Within the third model there was no hierarchical inclusion of the vari-
ables. All variables were entered as dummies, except for age, BNP,
QoL scales, systolic blood pressure, diastolic blood pressure, heart
rate, sodium, and estimated glomerular filtration rate (eGFR), which
were modelled as continuous variables. The RAND36 dimensions
and the total score of the MLwHFQ were recoded per 10 units. To
gain hazard ratios (HRs) .1.00 for reasons of readability, the scores
of the RAND36 dimensions per 10 units and the Ladder of Life
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scores were subtracted from 10. All QoL scales were stratified by
centre.
More in-depth analyses on patient characteristics of the two QoL
dimensions with the highest prediction on survival were performed.
We compared patients who scored in the lowest quartiles with
patients who scored in the highest quartiles on these dimensions.
Kaplan–Meier curves with a log-rank test were constructed for the
patients in the lowest and highest quartiles of both dimensions.
Statistical significance was set at two-tailed P, 0.05. Analyses were




Of the 1023 patients included in the main COACH study, a BNP
level was available in 766 patients. Within the patient sample of
766 patients, all QoL questionnaires at baseline were completed
by 661 patients (86%). Only patients with available BNP levels
who completed all questionnaires were included in the current
study. Patients who were excluded from the current study did
not differ from the study sample on age, gender, NYHA functional
class at discharge, and LVEF function.
Patients had a mean age of 71 years (+ 11), 61% was male, and
40% were living alone. The mean LVEF was 34% (+ 14), 33% had
an LVEF .40%, and at discharge 51% were classified as NYHA
functional class III– IV (Table 1). During the 3-year follow-up, 276
(42%) patients died; no patients were lost to follow-up. Patients
who died during the follow-up period were significantly older,
more often in NYHA III– IV, had higher BNP levels at hospital dis-
charge, lower systolic and diastolic blood pressure, lower eGFRs,
had been diagnosed with HF for longer, were more often previous-
ly hospitalized for HF, and were more often diagnosed with dia-
betes or had a stroke in the past than patients who survived the
3-year follow-up period. Furthermore, the survivors were more
often treated with angiotensin-converting enzyme (ACE) inhibi-
tors/angiotensin receptor blockers (ARBs) and beta-blockers at
discharge than the non-survivors (Table 1).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics according to mortality
Total group (n 5 661) Survivors (n 5 385) Non-survivors (n5 276) P-valuea
Demographics
Age (years) 71+11 68+12 74+10 ,0.001
Male 62% 58% 64% 0.147
Living alone 40% 39% 42% 0.336
Smoking 17% 18% 15% 0.290
Clinical characteristics
LVEF % 34+14 34+14 34+14 0.916
NYHA III– IV 51% 45% 59% ,0.001
Systolic blood pressure (mmHg) 118+21 120+21 116+20 0.039
Diastolic blood pressure (mmHg) 69+12 70+12 66+12 ,0.001
Heart rate (b.p.m.) 75+13 75+14 74+12 0.409
BNP (pg/mL) median (IQR) 447 (202–869) 342 (161–725) 572 (300–1110) ,0.001
Sodium (mEq/L) 139+4.7 139+4.6 138+4.9 0.186
eGFR (mL/min/1.73 m2) 57+22 61+22 50+20 ,0.001
Hypertension 44% 44% 43% 0.968
Ischaemic heart failure 42% 38% 46% 0.041
Duration of heart failure (years) 2.7+4.5 2.0+3.8 3.7+5.1 ,0.001
. 1 previous heart failure hospitalization 33% 26% 43% ,0.001
Medication
ACE inhibitors/ARB 84% 87% 81% 0.030
Beta-blockers 65% 68% 61% 0.043
Diuretics 97% 96% 98% 0.121
Co-morbidities
COPD 27% 25% 29% 0.180
Diabetes 28% 23% 34% 0.001
Stroke 9% 7% 12% 0.029
Renal disease 7% 7% 8% 0.444
aComparison between survivors and non-survivors.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; eGFR, estimated
glomerular filtration rate; IQR, interquartile range; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional class.
T. Hoekstra et al.96







Global well-being at baseline, as measured with Cantril’s Ladder of
Life, did not differ significantly between survivors and non-
survivors (6.3+ 1.7 vs. 6.2+1.9, P ¼ 0.170).
Mean scores of all dimensions of the RAND36 in the total group
varied between 18 and 66 on the theoretical range between 0 and
100, with the lowest scores for role limitations physical (18+33),
health change (25+23), and physical functioning (34+26). Non-
survivors had a significantly lower QoL at baseline than survivors
on the physical functioning (28+23 vs. 39+ 27, P, 0.001),
role limitations physical (13+ 27 vs. 22+36, P, 0.001), bodily
pain (60+34 vs. 66+ 34, P ¼ 0.031), and general health (41+
18 vs. 46+19, P ¼ 0.001) dimensions (Figure 1).
The mean score in the total group on the total scale of the
MLwHFQ was 44+21. On the physical and emotional subscales,
mean scores were 24+ 23 and 7.1+ 6.1, respectively. On the
MLwHFQ, non-survivors rated their QoL at baseline significantly
lower than survivors on the total score (47+ 19 vs. 42+ 22,
P ¼ 0.010) and the physical subscale (25+9 vs. 22+ 11, P ¼
0.001). The emotional subscale scores of the MLwHFQ at baseline
did not differ between survivors and non-survivors (6.9+6.1 vs.
7.3+ 6.1, P ¼ 0.380).
Survival analyses
Univariate analyses (model 1) show a HR of 1.15 (95% confidence
interval1.09–1.21) per 10 units on the physical functioning dimen-
sion of the RAND36, which indicates an increase of 15% in mor-
tality per 10 units decrease on the physical functioning score.
Furthermore, a decrease in scores per 10 units on the role limita-
tions physical, bodily pain, and general health dimensions of the
RAND36 showed a significant increase in mortality (8, 4, and
12%, respectively). An increase in score per 10 units on the total
score of the MLwHFQ and per one unit on the physical functioning
score of the MLwHFQ also showed a significant increase of 7% and
2% in mortality (Table 2).
After adjusting the model for age, gender, NYHA, smoking, sys-
tolic blood pressure, diastolic blood pressure, heart rate, BNP
level, sodium level, eGFR, ischaemic HF, duration of disease, previ-
ously hospitalized for heart failure more than once, ACE inhibitors/
ARBs, beta-blockers, diuretics, diabetes, stroke, and renal disease
(model 3), the physical functioning and general health dimensions
of the RAND36 were associated with mortality (Table 2).
Patient characteristics related to low
physical functioning and general health
Patient characteristics were compared between patients who
scored in the lowest quartile of physical functioning (range
0–15) and general health (range 0–30) and the highest quartile
(ranges 50–100 and 55–100, respectively). Patients with a low
QoL on physical functioning were older, more often female,
more often in NYHA III– IV, had higher BNP levels at discharge,
lower sodium levels, lower diastolic blood pressure, lower
eGFRs, were more often diagnosed with chronic obstructive pul-
monary disease (COPD), diabetes, and stroke, had a longer dur-
ation of HF, were more often previously hospitalized for HF, and
less often had a prescription of beta-blockers at discharge, than
patients with high physical functioning (Table 3).
Patients with a low QoL on the general health dimension were
also more often in NYHA III– IV, diagnosed with COPD and
stroke, had suffered longer from HF, were more often previously
hospitalized for HF, had lower eGFRs, and were more often diag-
nosed with renal disease than patients with a high QoL on the
general health dimension (Table 3).
During the 3-year follow-up period, 84 of the 157 patients (54%)
with a low physical functioning score, and 39 of the 151 patients
(26%) with a high physical functioning score, died (P, 0.001,
Figure 2). Of the 133 patients with a low general health score, 75
patients (56%) died, compared with 54 of the 153 patients (35%)
with a high general health score (P, 0.001, Figure 3).
Figure 1 Quality of life as measured by the RAND36 at baseline according to mortality.
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The main finding of the present study is that QoL independently of
BNP values predicts 3-year mortality in patients with HF. To our
knowledge this is the first study in a large and clinically relevant
group of HF patients in which the effect of QoL on mortality is
adjusted for BNP levels, a widely accepted marker for disease se-
verity and a prognostic tool to predict mortality.11,22
Previous research showed inconsistent results on physical QoL
to be a predictor of mortality.3 When looking at the four studies
which used a disease-specific QoL questionnaire and had a follow-
up period. 2 years, all studies found a significant association
between the physical component of their questionnaire and mor-
tality.6,7,23,24 However, our results on the physical dimension of the
MLwHFQ being a predictor for survival independent of BNP levels
do not confirm these findings. Studies including the physical dimen-
sions of disease-generic QoL questionnaires to predict mortality
are not consistent.6,7,25,26 Two studies did find physical functioning
to be independently associated with mortality,7,25 and two other
studies did not find this association.6,24 However, these two
studies had limitations in the generalizability of their results due
to their relatively small sample size26 and a very specific HF
patient sample, namely male veterans.6 Both studies which
showed consistent findings had a relatively large (n ¼ 3375 and
n ¼ 433) and a more generalizable HF patient sample.7,25
In our study we extend previous studies by taking the research
to the next level by exploring which patients report low QoL in
order to address future interventions for improving QoL, and re-
ducing mortality. In our data we found several factors related to
low QoL that could be used in identifying patients with low
QoL, e.g. higher age, female gender, being diagnosed with HF for
longer, and co-morbidities. Other factors related to low QoL
which can be used to identify patients, but which also can be influ-
enced by interventions and therefore possibly improve QoL, are
high NYHA functional class (III– IV), low eGFRs, and no prescrip-
tion of beta-blockers.
To improve NYHA functional class, it can be suggested to
include an exercise component in the treatment programmes of
HF patients. Several studies have shown that exercise programmes
improve QoL.27 Two meta-analyses of exercise-based rehabilita-
tion clinical trials in patients with HF identified a significant
benefit of exercise training on all-cause mortality and total
cardiac mortality.28,29 Furthermore, our results show that patients
with a low QoL had fewer beta-blocker prescriptions. The effect-
iveness of beta-blockers for mortality is well tested,1 and showed a
trend towards improvement of QoL in patients receiving beta-
blocker therapy.30
The current study underlines the importance of QoL in patients
with HF.31 Previous research on patients’ preferences show that
patients give equal or more importance to QoL when compared
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 2 Cox proportional hazards regression of the quality of life subscales on time to mortality (n 5 661)
Model 1 Model 2 Model 3
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Ladder of Lifea
Well-being 1.04 (0.98–1.11) 0.222 1.05 (0.98–1.12) 0.148 1.01 (0.94–1.08) 0.738
RAND36 (per 10 units)a
Physical functioning 1.15 (1.09–1.21) ,0.001 1.13 (1.07–1.20) ,0.001 1.08 (1.02–1.14) 0.008
Social functioning 1.01 (0.97–1.05) 0.576 1.02 (0.99–1.06) 0.343 0.98 (0.95–1.02) 0.438
Role limitations—physical 1.08 (1.03–1.13) 0.001 1.08 (1.04–1.13) ,0.001 1.04 (0.99–1.08) 0.128
Role limitations—emotional 1.02 (1.00–1.05) 0.055 1.02 (1.00–1.05) 0.071 1.01 (0.98–1.04) 0.559
Mental health 1.03 (0.98–1.08) 0.289 1.06 (1.00–1.11) 0.032 1.04 (0.99–1.10) 0.150
Vitality 1.05 (1.00–1.11) 0.053 1.07 (1.02–1.13) 0.007 1.03 (0.98–1.09) 0.256
Bodily pain 1.04 (1.00–1.08) 0.029 1.04 (1.00–1.07) 0.044 1.03 (0.99–1.07) 0.109
General health 1.12 (1.05–1.20) 0.001 1.13 (1.06–1.21) ,0.001 1.08 (1.01–1.16) 0.032
Health change 1.01 (0.96–1.06) 0.681 1.02 (0.96–1.07) 0.557 1.00 (0.95–1.05) 0.923
Minnesota Living with Heart Failure Quesionnaireb
Total (per 10 units) 1.07 (1.02–1.13) 0.012 1.12 (1.06–1.19) ,0.001 1.05 (0.98–1.12) 0.172
Physical functioning 1.02 (1.01–1.03) 0.002 1.02 (1.01–1.03) ,0.001 1.01 (0.99–1.02) 0.350
Emotional functioning 1.01 (0.99–1.03) 0.302 1.03 (1.01–1.05) 0.012 1.01 (0.99–1.03) 0.304
Model 1: no adjustments
Model 2: adjustment for age and gender
Model 3: adjustment for age, gender, smoking, New York Heart Associtiation, systolic blood pressure, diastolic blood pressure, heart rate, brain natriuretic peptide level, sodium
level, estimated glomerular filtration rate, ischaemic heart failure, duration of disease, previously hospitalized for heart failure more than once, angiotensin-converting enzyme
inhibitors/angiotensin receptor blocker, beta-blockers, diuretics, diabetes, stroke, and renal disease.
CI, confidence interval; HR, hazard ratio.
aA higher score means better health.
bA higher score means worse health.
T. Hoekstra et al.98






with length, and about half of a HF patient population is willing to
select therapies that improve their QoL, even if this leads to short-
ening of life,32,33 although one study showed the opposite results.34
In the past, study outcomes focused mainly on reducing hospitali-
zations and mortality. Nowadays, QoL is increasingly incorporated
as an outcome measure in clinical trials.35– 37 Furthermore, in the
HF guidelines, improving QoL is recognized as one of the major
treatment goals.15 Adding our findings that QoL is independently
associated with mortality, to the relevance of QoL for individual
patients, for research outcomes, and for clinical practice, the
value of QoL cannot be ignored. It is of great importance to
develop and evaluate treatment programmes that effectively
improve QoL in HF patients. However, there are few randomized
studies that specifically focus on improving QoL in patients with
HF. Some studies on disease management programmes have
shown improvement in QoL as a result; unfortunately, the findings
are inconsistent.38
It might be debated that the concepts QoL and depression are
overlapping. Quality of life is defined by the World Health Organ-
ization as ‘an individual’s perception of their position in life in the
context of the culture and value systems in which they live and
in relation to their goals, expectations, standards and concerns’.39
Depression is defined by the DSM-IV (Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition) as a mental disorder
that presents with depressed mood, loss of interest or pleasure,
weight loss, feelings of guilt or low self-worth, disturbed sleep or
appetite, fatigue and poor concentration, and can be classified
under the heading of the psychological function of the QoL
domains.40 From our COACH database, we previously published
data that showed that 39% of patients with HF had depressive
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .













Age (years) 74+10 67+11 ,0.001 70+12 72+11 0.301
Male 47% 72% ,0.001 56% 59% 0.678
Living alone 46% 36% 0.079 39% 46% 0.256
Smoking 16% 19% 0.433 12% 18% 0.177
Clinical characteristics
LVEF % 34+15 32+14 0.219 35+15 35+15 0.975
NYHA III– IV 69% 26% ,0.001 66% 33% ,0.001
Systolic blood pressure (mmHg) 117+22 121+21 0.109 115+21 120+21 0.055
Diastolic blood pressure (mmHg) 67+13 71+12 0.007 68+13 70+12 0.103
Heart rate (b.p.m.) 75+13 74+14 0.474 74+14 73+13 0.536
BNP (pg/mL) median (IQR) 497 (244–1090) 348 (162–747) 0.017 502 (232–1070) 389 (179–801) 0.125
Sodium (mEq/L) 137+5.9 139+4.3 ,0.001 138+5.3 139+5.2 0.087
eGFR (mL/min/1.73 m2) 51+19 62+21 ,0.001 52+22 58+19 0.021
Hypertension 47% 42% 0.399 44% 39% 0.452
Ischaemic heart failure 39% 40% 0.874 39% 42% 0.561
Duration of heart failure (years) 3.6+5.1 1.4+2.8 ,0.001 3.8+5.5 1.6+3.6 ,0.001
. 1 previous heart failure hospitalization 47% 24% ,0.001 47% 22% ,0.001
Medication
ACE inhibitors/ARB 82% 89% 0.076 84% 86% 0.739
Beta-blockers 58% 73% 0.006 64% 67% 0.625
Diuretics 97% 95% 0.511 97% 97% 0.900
Co-morbidities
COPD 33% 14% ,0.001 35% 12% ,0.001
Diabetes 39% 21% ,0.001 25% 20% 0.290
Stroke 13% 5% 0.023 16% 4% 0.001
Renal disease 7% 6% 0.710 11% 3% 0.008
Quality of life
Physical functioninga 6+4 74+15 ,0.001 21+19 50+29 ,0.001
General healtha 36+17 55+18 ,0.001 19+7 70+9 ,0.001
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; eGFR, estimated
glomerular filtration rate; IQR, interquartile range; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional class.
aA higher score means better health.
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symptoms [Center for Epidemiological Studies Depression scale
(CES-D) score ≥16], and having severe depressive symptoms
was significantly associated with death and readmission within 18
months of follow-up after a hospital admission.41 In the current
study we did not include depressive symptoms measured by the
CES-D, but did include several mental health and emotional dimen-
sions of the different QoL questionnaires. These dimensions
include fewer items than the CES-D, and are not specifically
focused on depression, but more on emotions and mental health
in general.
The present study is limited, in that the follow-up period for
mortality was 3 years, which is relatively short compared with
other studies on QoL being a predictor for long-term mortality
which have used follow-up periods of 5– 7 years.6,7 However,
our sample size was relatively large (n ¼ 661) compared with
the previous studies on long-term mortality, which had sample
sizes of 459 and 416 HF patients, respectively. Furthermore, our
mortality rate was 42%, which is comparable with the mortality
rates of both the other long-term follow-up studies (e.g. 44%
and 70%) and therefore high enough for reliable analyses on com-
paring QoL between survivors and non-survivors. A second limita-
tion is generalizability of the study cohort. Only hospitalized
patients with HF were included, which is only a part of the total
HF patient population.
In conclusion, the present study is the first study on QoL and
long-term mortality in HF in which BNP levels were used as an
Figure 2 Kaplan–Meier curves for time to death in patients with low physical functioning and high physical functioning.
Figure 3 Kaplan–Meier curves for time to death in patients with low general health and high general health.
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objective marker to reflect the severity of HF. Our results show
that QoL assessed during a hospitalization for HF is a predictor
for 3-year mortality independent of BNP levels and a wide range
of demographical and clinical variables. In particular, general
health and physical functioning assessed with a disease-generic
QoL questionnaire provide prognostic information on survival in
addition to other prognostic variables. Patients with low scores
on these dimensions were more likely to be in NYHA III– IV, diag-
nosed with co-morbidities, suffered from HF for longer, had lower
eGFRs, and had fewer beta-blocker prescriptions.
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